PER-009-04Completed未知
STUDY OF EVALUATION OF PERIOPERATIVE ISCHEMIA (POISE)
POPULATION HEALTH RESEARCH INSTITUTE DE LA UNIVERSIDAD MC MASTER DE CANADA,0 sites0 target enrollmentStarted: April 23, 2004Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 0 to 0 (—)
Inclusion Criteria
- •1. They are> 45 years old
- •2. They have an expectation of postoperative stay> at 24 hours for surgical reasons
- •3. Meet any of the following 6 criteria:
- •A. history of coronary artery disease
- •B. Vascular artery disease
- •C. History of Stroke
- •D. Hospitalization by ICC within 3 years prior to randomization.
- •E. Patients going to vascular surgery
Exclusion Criteria
- •1. Contraindication for metoprolol
- •2. There is a clinical need for beta-blocker use preoperatively or during the first 30 days postoperatively
- •3. Previous adverse reaction to a beta blocker
- •4. Coronary revascularization surgery in the previous 5 years and no evidence of cardiac ischemia since surgery
- •5. Patients who undergo low-risk surgical procedures
Investigators
Similar Trials
Completed
Not Applicable
Perioperative ischemic evaluation study (POISE study)CardiovascularCirculatory SystemISRCTN17233551McMaster University (Canada)10,000
Recruiting
Phase 3
â??Evaluation of tranexamic acid compared with placebo among patients with or at risk of heart disease undergoing surgeries not related to the heart, on bleeding and blood vessel occlusive outcomesCTRI/2019/06/019833Population Health Research Institute
Active, not recruiting
Phase 1
Evaluation of strategies aiming at controlling perioperative ischemia - 3 (POISE-3)The occurrence of life-threatening, major, and critical organ bleeding in patients who are undergoing noncardiac surgery.MedDRA version: 23.1Level: LLTClassification code 10051014Term: Post procedural bleedingSystem Organ Class: 100000004863EUCTR2018-000539-29-ITHamilton Health Sciences Corporation10,000
Completed
Phase 3
Peri-Operative ISchemic Evaluation-3 Trialvascular events1001928010023213heart failureNL-OMON48217Population Health Research Institute400
Active, not recruiting
Not Applicable
eriOperative ISchemic Evaluation-2 TrialEUCTR2009-018173-31-ATPopulation Health Research Institute10,000